WMT

131.04

+3.47%↑

COST

1,013.74

+2.53%↑

146.95

+0.38%↑

166.24

+1.99%↑

PEP

158.33

+2.65%↑

WMT

131.04

+3.47%↑

COST

1,013.74

+2.53%↑

146.95

+0.38%↑

166.24

+1.99%↑

PEP

158.33

+2.65%↑

WMT

131.04

+3.47%↑

COST

1,013.74

+2.53%↑

146.95

+0.38%↑

166.24

+1.99%↑

PEP

158.33

+2.65%↑

WMT

131.04

+3.47%↑

COST

1,013.74

+2.53%↑

146.95

+0.38%↑

166.24

+1.99%↑

PEP

158.33

+2.65%↑

WMT

131.04

+3.47%↑

COST

1,013.74

+2.53%↑

146.95

+0.38%↑

166.24

+1.99%↑

PEP

158.33

+2.65%↑

Home・Akcijų sąrašas・USANA Health Sciences Inc

USANA Health Sciences Inc

Atidarymo kaina

18.51 -4.54

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.43

Max

19.3

Pagrindiniai rodikliai
By Trading Economics
Pajamos	5.1M -1.6M
Pardavimai	13M 226M
P/E Sektoriaus vid.	33.414 28.392
Pelno marža	-0.705
Darbuotojai	1,570
EBITDA	16M 28M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-24M 358M
Ankstesnė atidarymo kaina	23.05
Ankstesnė uždarymo kaina	18.51

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

28.405 / 29.84 Palaikymas ir pasipriešinimas

USANA Health Sciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 23:53; UTC

Uždarbis

Naver Posts Weaker First-Quarter Earnings

2026-04-29 23:41; UTC

Karštos akcijos

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

2026-04-29 23:55; UTC

Uždarbis

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-29 23:54; UTC

Uždarbis

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

2026-04-29 23:52; UTC

Uždarbis

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

2026-04-29 23:51; UTC

Uždarbis

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

2026-04-29 23:51; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

2026-04-29 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

2026-04-29 23:22; UTC

Uždarbis

China Longyuan 1Q Net CNY1.70B, Down 14%

2026-04-29 23:22; UTC

Uždarbis

China Longyuan: Power Generation Down 2.9% as of End-March

2026-04-29 23:20; UTC

Uždarbis

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

2026-04-29 23:20; UTC

Uždarbis

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss Narrows>000002.SZ

2026-04-29 23:18; UTC

Uždarbis

Naver1Q Net Profit Missed FactSet-Compiled Consensus

2026-04-29 23:17; UTC

Uždarbis

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

2026-04-29 23:13; UTC

Uždarbis

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

2026-04-29 23:12; UTC

Uždarbis

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

2026-04-29 23:04; UTC

Uždarbis

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

2026-04-29 23:04; UTC

Uždarbis

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Akcijų palyginimas

Kainos pokytis

USANA Health Sciences Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių USANA Health Sciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

28.405 / 29.84Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę USANA Health Sciences Inc

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.